Inactive Instrument

Highlights Jaguar Health Inc Nasdaq

Equities

US47008L1061

Highlights

Unlock all the news: Be the first to know and act before the market!

Jaguar Health Unit Secures New European, Australian Patents; Shares Rise	07-08	MT
Top Premarket Gainers	05-30	MT
Jaguar Health Expands Out-licensing Agreement With Magdalena Biosciences	05-29	MT
Jaguar Health, Inc. Executes Out- License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia	05-29	CI
Jaguar Health, Inc. Announces Results of Third-Party, Investigator-Initiated Study of Crofelemer	05-28	CI
Jaguar Health Plans 1-for-60 Reverse Split Next Week	05-17	MT
Earnings Flash (JAGX) JAGUAR HEALTH Reports Q1 Revenue $2.4M, vs. Street Est of $3M	05-14	MT
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration	05-06	CI
Venture Life renews revolving credit facility with Santander and HSBC	04-19	AN
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected	04-10	MT
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes	04-10	MT
Top Premarket Gainers	04-10	MT
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study	02-15	MT
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs	02-15	CI
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II	12-11	CI
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs	12-04	CI
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Jaguar Health Gets Additional 180-Day Grace Period to Regain Nasdaq Compliance	11-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Jaguar Health Inc Nasdaq

Equities

US47008L1061

Highlights

Filters